Anti-indoleamine 2,3-dioxygenase 1 antibodies and diagnostic uses thereof
The invention provides antibodies that bind specifically to human indoleamine 2,3-dioxygenase 1 (IDO1), and methods of using the same. The antibodies are capable of binding to a sequence comprising SEQ ID NO: 1 and specifically bind to human IDO1 in formalin fixed paraffin embedded tissues. The antibodies are useful in a number of different analytical techniques, including immunohistochemistry (IHC) and immunocytochemistry (ICC).
1. An isolated antibody capable of binding specifically to a region of human indoleamine 2,3-dioxygenase 1 (IDO1) comprising SEQ ID NO: 1 in formalin-fixed paraffin embedded tissue, wherein the antibody comprises the following light chain (L) hypervariable regions (HVR) and heavy chain (H) hypervariable regions (HVR):
(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 2;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 3;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 4;
(d) an HVR-L comprising the amino acid sequence of SEQ ID NO: 9;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 10; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 11.
2. The antibody of claim 1 , further comprising the following heavy chain variable domain framework regions (FRs):
(a) FR-H1 comprising the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 19;
(b) FR-H2 comprising the amino acid sequence of SEQ ID NO: 6;
(c) FR-H3 comprising the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 20; and
(d) FR-H4 comprising the amino acid sequence of SEQ ID NO: 8.
3. The antibody of claim 1 , further comprising the following light chain variable domain FRs:
(a) FR-L1 comprising the amino acid sequence of SEQ ID NO: 12;
(b) FR-L2 comprising the amino acid sequence of SEQ ID NO: 13;
(c) FR-L3 comprising the amino acid sequence of SEQ ID NO: 14; and
(d) FR-L4 comprising the amino acid sequence of SEQ ID NO: 15.
4. The antibody of claim 1 , wherein the antibody further comprises the following heavy chain variable domain and light chain variable domain framework regions (FR):
(a) FR-H1 comprising the amino acid sequence of SEQ ID NO: 5;
(b) FR-H2 comprising the amino acid sequence of SEQ ID NO: 6;
(c) FR-H3 comprising the amino acid sequence of SEQ ID NO: 7;
(d) FR-H4 comprising the amino acid sequence of SEQ ID NO: 8;
(e) FR-L1 comprising the amino acid sequence of SEQ ID NO: 12;
(f) FR-L2 comprising the amino acid sequence of SEQ ID NO: 13;
(g) FR-L3 comprising the amino acid sequence of SEQ ID NO: 14; and
(h) FR-L4 comprising the amino acid sequence of SEQ ID NO: 15.
5. The antibody of claim 1 , wherein the antibody is an IgG antibody.
6. An immunoconjugate comprising the antibody of claim 1 .
7. The antibody of claim 1 , comprising a variable domain of the heavy chain (V H ) sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 16.
8. The antibody of claim 7 , wherein the V H sequence comprises SEQ ID NO: 16.
9. The antibody of claim 1 , wherein the antibody is a monoclonal antibody.
10. The antibody of claim 9 , wherein the monoclonal antibody is a rabbit monoclonal antibody.
11. The antibody of claim 1 , wherein the antibody is an antibody fragment that specifically binds IDO1.
12. The antibody of claim 11 , wherein the antibody fragment is selected from the group consisting of Fab, single chain variable fragment (scFv), Fv, Fab′, Fab′-SH, F(ab′)2, and diabody.
13. The antibody of claim 7 , further comprising a variable domain of the light chain (V L ) sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 17.
14. The antibody of claim 13 , wherein the V L sequence comprises SEQ ID NO: 17.
15. The antibody of claim 13 , wherein the V H sequence comprises SEQ ID NO: 16 and the V L sequence comprises SEQ ID NO: 17.